AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Regeneron backs $75M series A for antibody upstart Infinimmune

Companies Attending Our 10^th Anniversary Include: AbbVie, Galderma, Merck, Eli Lilly, Sun Pharma, AOBiome, Navigator Medicines, and lots more - View the Event Guide

From Preclinical Models to Clinical Biomarkers: An Integrated Approach to Target Validation and Clinical Translation

10:30 am - Thursday 5th November 2026

Translational case studies demonstrating how preclinical dermatology assays can support target validation, mechanism-of-action research, and candidate selection
Advanced in vitro, ex vivo, and in vivo models designed to generate clinically relevant evidence before clinical development
Biomarker analysis in clinical samples to confirm biological activity, monitor treatment response, and strengthen clinical research outcomes

Kelsey Retting

Senior Business Development Manager

QIMA Life Sciences